Back to search results

ADAPT Study: Understanding Weight Loss Plateaus

The ADAPT Study is looking for adults aged 18-60 with obesity (BMI 30.0-50.0 kg/m2) to understand why weight loss often stops, even when people try to continue losing weight. This study uses a Behavioral Weight Loss Program, a modified version of the Diabetes Prevention Program. Researchers want to see how your body's metabolism (how your body uses energy) and brain activity change as you lose weight and when you reach a weight loss plateau. Success in this study means understanding changes in your maximal respiratory capacity (how much oxygen your cells use) and brain activity (measured by fMRI BOLD signal) from the start of the study until you reach a weight loss plateau. The study aims to enroll 90 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 90 participants.
What's involved
You would enroll for 18 months, with 3 in-person study visits and a 6-month remote weight loss program. Some participants may have 3 additional in-person visits, which include questionnaires, blood draws, brain MRIs, body measurements, DXA scans, breathing tests, and tissue biopsies.
Compensation
Not stated in the trial record.
Follow-up
The study measures changes in maximal respiratory capacity and brain activity from baseline to a weight loss plateau, and tracks entry into an involuntary weight loss plateau throughout the 18-month enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06174389

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Recruiting
NAAges 18–60InterventionalBasic science
University of Washington
~90 participants
Updated 2025-08-29 on ClinicalTrials.gov
What's tested:Behavioral Weight Loss Program

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in maximal respiratory capacity (oxygen consumption rate) in peripheral blood mononuclear cells
Measured over From baseline to active weight loss (at least 21 days of weight loss equivalent or greater than 0.5 pounds per week) and from baseline to weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).
+2 more outcomes measured

Conditions

Obesity

Explore related trials

GliosisObesityWeight Change

Where it's being run

2 sites across 1 states
Washington2

Study leadership

  • Ellen Schur, MD, MS · PRINCIPAL_INVESTIGATOR · University of Washington
  • Marian Neuhouser, PhD, RD · PRINCIPAL_INVESTIGATOR · Fred Hutch Cancer Center

Who to contact

ADAPT Study
[email protected]
206-616-6360
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI 30.0 - 50.0 kg/m2
Able to attend study intervention classes and study visits/assessments
Independently living with access to food preparation facilities

Exclusion

Current smoker or regular use of nicotine containing products and/or cannabis
Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
Known cognitive impairments or h/o stroke
Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
History of bariatric surgery
History of eating disorder
Current participation in a formal weight loss program
Prior or current participation in a research study involving weight loss
Weight-reduced by \>10% within past year
Weight \> 330 pounds (MRI limit)
Allergy or intolerance to or unwillingness to consume study foods provided at visit
MRI contraindication (e.g., implanted metal, claustrophobia)
Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

What this trial measures

  • Change in maximal respiratory capacity (oxygen consumption rate) in peripheral blood mononuclear cellsFrom baseline to active weight loss (at least 21 days of weight loss equivalent or greater than 0.5 pounds per week) and from baseline to weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

    Mitochondrial maximal respiratory capacity will be measured in fasting samples from peripheral blood mononuclear cells.

  • Change in fMRI BOLD signalFrom baseline to a weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

    fMRI BOLD signal to visual food cues within a priori brain regions of interest pre and post consuming a standardized meal. Meal-induced change will be calculated by post-pre meal BOLD signal.

  • Entry into involuntary weight loss plateauthroughout 18-month enrollment

    binary outcome (Y/N) and time from baseline